EP1061800A4 - Compositions et methodes modulant la vascularisation - Google Patents

Compositions et methodes modulant la vascularisation

Info

Publication number
EP1061800A4
EP1061800A4 EP99912344A EP99912344A EP1061800A4 EP 1061800 A4 EP1061800 A4 EP 1061800A4 EP 99912344 A EP99912344 A EP 99912344A EP 99912344 A EP99912344 A EP 99912344A EP 1061800 A4 EP1061800 A4 EP 1061800A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods modulating
vascularization
modulating vascularization
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912344A
Other languages
German (de)
English (en)
Other versions
EP1061800A1 (fr
Inventor
Jeffrey M Isner
Takayuki Asahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Elizabeths Medical Center of Boston Inc
Original Assignee
Caritas St Elizabeth Medical Center of Boston
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caritas St Elizabeth Medical Center of Boston, St Elizabeths Medical Center of Boston Inc filed Critical Caritas St Elizabeth Medical Center of Boston
Publication of EP1061800A1 publication Critical patent/EP1061800A1/fr
Publication of EP1061800A4 publication Critical patent/EP1061800A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99912344A 1998-03-09 1999-03-09 Compositions et methodes modulant la vascularisation Withdrawn EP1061800A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7726298P 1998-03-09 1998-03-09
US77262P 1998-03-09
PCT/US1999/005130 WO1999045775A1 (fr) 1998-03-09 1999-03-09 Compositions et methodes modulant la vascularisation

Publications (2)

Publication Number Publication Date
EP1061800A1 EP1061800A1 (fr) 2000-12-27
EP1061800A4 true EP1061800A4 (fr) 2004-10-06

Family

ID=22137044

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912344A Withdrawn EP1061800A4 (fr) 1998-03-09 1999-03-09 Compositions et methodes modulant la vascularisation

Country Status (5)

Country Link
EP (1) EP1061800A4 (fr)
JP (2) JP2002506008A (fr)
AU (1) AU766238B2 (fr)
CA (1) CA2322559C (fr)
WO (1) WO1999045775A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412436C (fr) 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
AU7549501A (en) * 2000-06-16 2002-01-02 Biogen Inc Angiogenesis-modulating compositions and uses
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
KR20030034177A (ko) 2000-09-13 2003-05-01 쥬가이 세이야쿠 가부시키가이샤 허혈성 질환 치료제
CA2426819A1 (fr) * 2000-10-30 2002-05-10 Children's Medical Center Corporation Structures vasculaires de synthese
US20040265971A1 (en) * 2001-11-19 2004-12-30 Hidetaka Sato Drug mobilizing pluripotent stem cells from tissue into peripheral blood
JPWO2003059375A1 (ja) * 2002-01-17 2005-05-19 株式会社カルディオ 組織再生複合療法
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
JP2005539031A (ja) * 2002-08-16 2005-12-22 シエーリング アクチエンゲゼルシャフト 野生型または変異型ｅＮＯＳによる重症肢虚血の遺伝子療法
CN100366257C (zh) * 2002-08-22 2008-02-06 克里夫兰诊所基金会 基质细胞衍生因子-1介导缺血性心肌病中干细胞归巢及组织再生
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
AU2008200822A1 (en) * 2002-08-22 2008-03-13 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CA2509618A1 (fr) * 2002-12-13 2004-07-01 Hisayoshi Fujiwara Compositions pharmaceutiques destinees au traitement d'une insuffisance cardiaque non-ischemique
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
CA2563329C (fr) * 2004-04-30 2016-01-26 Orbus Medical Technologies, Inc. Dispositif medical dote d'un revetement servant a capter des cellules modifiees genetiquement et methodes d'utilisation associees
JP5031370B2 (ja) * 2004-09-17 2012-09-19 セルジェンテック株式会社 外用皮膚潰瘍治療剤
JPWO2006075587A1 (ja) * 2005-01-11 2008-06-12 国立大学法人名古屋大学 Ｃｓｆ含有低用量投与用治療剤
JPWO2006093172A1 (ja) * 2005-02-28 2008-08-07 財団法人先端医療振興財団 成体幹細胞の体外増幅方法
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
US8247374B2 (en) 2007-11-09 2012-08-21 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
CA2743682A1 (fr) 2007-11-30 2009-06-11 New York Medical College Procedes permettant de reduire le rejet de greffon et l'arteriosclerose acceleree du greffon cardiaque par implantation de cellules souches autologues
CA2743698A1 (fr) 2007-11-30 2009-06-11 New York Medical College Compositions comprenant des cellules progenitrices vasculaires et myocytaires et procedes permettant de les utiliser
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
CA2709398C (fr) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Utilisation du facteur 1 derive de cellules stromales afin de favoriser la guerison des plaies
KR101290322B1 (ko) 2008-04-09 2013-07-26 주식회사 바이로메드 플라스미드 ｄｎａ의 발현 증강용 동결건조 ｄｎａ 제제
JP5856059B2 (ja) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション 虚血組織を治療するためのｓｄｆ−１送達
KR101609690B1 (ko) * 2011-04-26 2016-04-06 아주대학교산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
WO2012148200A2 (fr) * 2011-04-26 2012-11-01 아주대학교 산학협력단 Composition pour faciliter des procédures chirurgicales pour traiter des maladies vasculaires ischémiques
KR101336386B1 (ko) * 2011-06-17 2013-12-04 전북대학교병원 림프관 생성 유도제
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
US11744858B2 (en) 2015-03-18 2023-09-05 Foundation For Biomedical Research And Innovation At Kobe Medicine for treatment and/or prevention of ischemic diseases, method for improving angiogenesis-promoting activity of cells, or method for producing medicine
AU2019305221B2 (en) 2018-07-19 2024-11-07 Helixmith Co., Ltd. Lyophilized pharmaceutical compositions for naked DNA gene therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019712A1 (fr) * 1996-11-08 1998-05-14 St. Elizabeth's Medical Center Of Boston, Inc. Procede de regulation de l'angiogenese

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808042A (en) * 1982-06-11 1989-02-28 Electro-Plasma, Inc. Powder feeder
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019712A1 (fr) * 1996-11-08 1998-05-14 St. Elizabeth's Medical Center Of Boston, Inc. Procede de regulation de l'angiogenese

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASAHARA TAKAYUKI ET AL: "Vasculogenesis, developed by endothelial progenitor cells, has significant role in neovascularization in severe ischemia", CIRCULATION, vol. 96, no. 8 SUPPL., 21 October 1997 (1997-10-21), & 70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; ORLANDO, FLORIDA, USA; NOVEMBER 9-12, 1997, pages I415 - I416, XP008033796, ISSN: 0009-7322 *
FLAMME INGO ET AL: "Induction of vasculogenesis and hematopoiesis in vitro", DEVELOPMENT (CAMBRIDGE), vol. 116, no. 2, 1992, pages 435 - 439, XP002291992, ISSN: 0950-1991 *
KALKA C ET AL: "Angiogenese und Vaskulogenese", HERZ, URBAN UND VOGEL, MUENCHEN, DE, vol. 25, no. 6, 2000, pages 611 - 622, XP002971995, ISSN: 0340-9937 *
See also references of WO9945775A1 *

Also Published As

Publication number Publication date
JP2010265301A (ja) 2010-11-25
WO1999045775A1 (fr) 1999-09-16
CA2322559A1 (fr) 1999-09-16
JP2002506008A (ja) 2002-02-26
EP1061800A1 (fr) 2000-12-27
AU766238B2 (en) 2003-10-09
AU3073799A (en) 1999-09-27
CA2322559C (fr) 2012-07-17

Similar Documents

Publication Publication Date Title
FR2781666B1 (fr) Composition cosmetique solide et ses utilisations
DE69918233D1 (de) Polymilchsäure zusammensetzung und daraus hergestellter film
NO20005913D0 (no) Legemiddelsammensetning
HRP20120132A8 (hr) Azabicikloalkani u svojstvu modulatora ccr5
ID26926A (id) Komposisi shampo pembentuk mode
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
DE69923810D1 (de) Blutstillendes Mittel
DK0945132T3 (da) Ibuprofen-præparat
ID27415A (id) Komposisi farmaseutik
ID29430A (id) Komposisi herbisida
ATE367845T1 (de) Riechstoffzusammensetzungen
NO20022334L (no) Ny sammensetning og anvendelse
NO20006488D0 (no) Sammensetning og anvendelse
ID29262A (id) Komposisi farmasi
DK1112003T3 (da) Ny sammensætning og anvendelse
DE69928862D1 (de) Zusammensetzung
DE69942892D1 (de) Gaserzeugende zusammensetzung
ID28752A (id) Metode-metode dan komposisi-komposisi sanitasi
DE69914470D1 (de) Gesundheitsfoerdernde gewuerzmittelzusammensetzung
DE69929516D1 (de) Bremsschuh und bremse
NO20000425D0 (no) Collagen type I og type III klebende sammensetninger
ID27201A (id) Komposisi farmasi
DE69930841D1 (de) Deodorantzusammensetzung
FR2778317B1 (fr) Composition edulcorante et ses utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CARITAS ST. ELIZABETH'S MEDICAL CENTER OF BOSTON,

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 35/28 B

Ipc: 7A 61K 35/14 B

Ipc: 7A 61K 38/19 B

Ipc: 7A 61K 38/18 B

Ipc: 7C 12Q 1/00 B

Ipc: 7A 01N 37/18 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040823

17Q First examination report despatched

Effective date: 20060926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503